REREX

Header iconREREX Comparison
Open Charts REREXBanner chart's image
American Funds EUPAC R4
Price$62.22
Change+$0.34 (+0.55%)
VolumeN/A
Net Assets136.27B
REREX Comparison Chart in %
Loading...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Market Cap

The average market capitalization across the group is 136.27B. The market cap for tickers in the group ranges from 136.27B to 136.27B. REREX holds the highest valuation in this group at 136.27B. The lowest valued company is REREX at 136.27B.

High and low price notable news

The average weekly price growth across all stocks in the group was 2%. For the same group, the average monthly price growth was 2%, and the average quarterly price growth was 10%. REREX experienced the highest price growth at 2%, while REREX experienced the biggest fall at 2%.

Volume

The average weekly volume growth across all stocks in the group was 0%. For the same stocks of the group, the average monthly volume growth was 0% and the average quarterly volume growth was 0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating:
P/E Growth Rating:
Price Growth Rating:
SMR Rating:
Profit Risk Rating:
Seasonality Score: (-100 ... +100)
Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
REREX
Total Expense Ratio0.82
Annual Report Gross Expense Ratio0.82
Fund Existence23 years
Gain YTD18.295
Front LoadN/A
Min. Initial Investment250
Min. Initial Investment IRAN/A
Net Assets136B
Annual Yield % from dividends0.70
Returns for 1 year9.68
Returns for 3 years39.27
Returns for 5 years12.11
Returns for 10 years42.02
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RMBS94.888.85
+10.29%
Rambus
LND3.920.14
+3.70%
BrasilAgro - Companhia Brasileira de Propriedades Agricolas
CCOI37.341.33
+3.69%
Cogent Communications Holdings
BPYPM16.480.29
+1.78%
Brookfield Property Partners LP
PRLD1.11-0.02
-1.77%
Prelude Therapeutics